AI Article Synopsis
- This study investigated the effectiveness of TORCH serology testing in pregnant women with suspected infections based on clinical signs, focusing on maternal versus fetal-related reasons for testing.
- Over 10 years, researchers analyzed data from 1,075 women, finding higher rates of TORCH infections, particularly cytomegalovirus (CMV), in those tested for maternal-related symptoms compared to those tested for fetal-related symptoms.
- The results suggest that while the overall benefits of TORCH testing for fetal issues were low, maternal symptoms should prompt testing, especially for CMV and Toxoplasma infections.
Article Abstract
Background: Clear guidelines have not been established about the utility of TORCH serology testing in women for whom TORCH infection is suspected according to clinical and laboratory manifestations during pregnancy. We aimed to compare rates of TORCH infections [specifically cytomegalovirus (CMV), Toxoplasma and rubella] in women who underwent TORCH serology testing due to maternal- versus fetal-related indications.
Methods: This 10-year single-center retrospective study included all the women beyond 24 weeks of gestation who underwent TORCH serology testing due to maternal- or fetal-related indications. Maternal-related indications included fever, gastroenteritis, elevated liver enzymes and thrombocytopenia. Fetal-related indications included intrauterine growth restriction, polyhydramnios and oligohydramnios.
Results: During the study period, 304 women underwent TORCH serology testing due to maternal-related indications and 771 due to fetal-related indications. For the maternal-related compared with the fetal-related indication group, maternal and congenital TORCH infections were more prevalent (P = 0.015), specifically CMV (P = 0.036). Eight (2.6%) of the women with maternal-related indications had a primary TORCH infection; 4 of them (50%) had concomitant congenital infections. Six (0.8%) of the women with fetal-related indications had a primary infection; none had a related congenital infection. Among the women with maternal-related indications, higher rates of maternal TORCH infection were found among those with thrombocytopenia (7.1%) and elevated liver enzymes (3.0%). During the study period, maternal-indicated TORCH testing detected 10.8% of neonates born with a confirmed TORCH infection.
Conclusions: The clinical yield of TORCH serology for nonspecific sonographic fetal features was low. Nonetheless, maternal-related indications should prompt testing for CMV and Toxoplasma infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/INF.0000000000004591 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Utility of Serologic TORCH Testing During Pregnancy for Maternal-related Versus Fetal-related Indications: A Retrospective Study.
Pediatr Infect Dis J
October 2024
From the Raya Strauss Wing of Obstetrics and Gynecology, Galilee Medical Center, Nahariya, Israel.
Article Synopsis
- This study investigated the effectiveness of TORCH serology testing in pregnant women with suspected infections based on clinical signs, focusing on maternal versus fetal-related reasons for testing.
- Over 10 years, researchers analyzed data from 1,075 women, finding higher rates of TORCH infections, particularly cytomegalovirus (CMV), in those tested for maternal-related symptoms compared to those tested for fetal-related symptoms.
- The results suggest that while the overall benefits of TORCH testing for fetal issues were low, maternal symptoms should prompt testing, especially for CMV and Toxoplasma infections.
Comparison of indications of pregnancy termination and prognosis of mothers and neonates in early- and late-onset preeclampsia.
Hypertens Pregnancy
August 2016
a Department of Obstetrics and Gynecology , International Peace Maternity and Child Health Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai , China.
Objective: To compare the indications of pregnancy termination and prognosis between early-onset preeclampsia (EOP) and late-onset preeclampsia (LOP).
Methods: In total, 100 patients diagnosed early-onset preeclampsia in our hospital from January 1, 2012, to June 30, 2014, were recruited for this retrospective cohort study. At the same time, we randomly chose another 100 late-onset preeclampsia as the contrast group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!